Richter And Stada Enter Biosimilar Development Deals

BMI View: The biosimilar licencing deals signed between Gedeon Richter and Stada are mutually beneficial, lowering the risks and costs associated with drug development and adding to the long-term sustainability of each firm's portfolio. However, there will be no immediate positive impact on revenues, with neither biosimilar involved set for commercialisation in the short term. We believe the unfavourable operating conditions in both companies' core European markets will be the ongoing and primary concern for these diversified generic drugmakers.

To read the full article, please choose one of the following options: